IL-SPHERA
Sphera, a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services, announces it has entered into an agreement to acquire riskmethods, a Munich, Germany-based, award-winning software company specializing in supply chain risk management (SCRM).
Founded in 2013, riskmethods’ software as a service (SaaS) solution harnesses cutting-edge artificial intelligence (AI), big data and machine learning to protect its customers’ supply chain networks. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with detailed status of suppliers, so they can prevent business disruption risk before it materializes and achieve supply chain transparency.
“riskmethods’ cloud-based software identifies, analyzes and helps mitigate all types of supply chain risk, including monitoring sustainability practices and ESG compliance in the supply chain. Their innovative approach to SCRM bolsters Sphera’s capabilities in offering a Scope 3 emissions monitoring and reporting solution and furthers our mission of creating a safer, more sustainable and productive world,” said Paul Marushka, Sphera’s president and CEO. “And their presence in Europe and the U.S. reinforces our ability to serve our expanding global customer base.”
The company’s SCRM software solution is a robust tool for managing risk in increasingly complex supply chains, as well as handling ever-expanding regulatory compliance. With global companies operating in a world of disruption and turbulence—pandemics and climate change, to name a few—riskmethods offers real-time SCRM solutions that enable businesses to proactively manage potential supply chain risks and comply with emerging operational and ESG regulations.
“For the last 10 years, riskmethods has been empowering businesses to master supply chain risk and create reliable supply networks,” said Heiko Schwarz, riskmethods’ CEO and founder. “Adding our advanced AI and machine-learning SCRM software solution to Sphera’s product portfolio will enable us to further our reach across the globe and help even more customers manage supply chain risk. We are excited to join the Sphera family of leading ESG software, data and consulting solutions.”
Kelly Wannop, Managing Director at Blackstone, said, “Blackstone’s 2021 investment in Sphera reflected our conviction in Sphera’s ESG mission and growth. The planned acquisition of riskmethods further demonstrates our commitment to helping Sphera expand their operational ESG solutions.” Eli Nagler, a Senior Managing Director at Blackstone, continued, “We are excited to welcome riskmethods to Sphera and eager to extend their SCRM solutions to even more customers.”
ReedSmith LLP and Simpson Thatcher & Bartlett LLP served as legal advisors to Sphera and Blackstone while Evercore served as the financial advisor. For the sellers, DLA Piper served as legal advisor, and Stifel served as the financial advisor.
About Sphera
Sphera is the leading provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services focusing on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. For more than 30 years, we have served over 6,700 customers and a million-plus users in 80 countries to help companies keep their people safe, their products sustainable and their operations productive. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.
About riskmethods
riskmethods enables organizations worldwide to identify, analyze and mitigate all types of supply chain risk management (SCRM). riskmethods’ software utilizes artificial intelligence (AI) and machine learning to protect its customers’ supply chain network. Its software platform collects supplier data and real-time information, distinguishes critical signals from “noise” and provides users with visibility across multiple tiers of their supply chain, so they can mitigate business disruption risk and achieve supply chain transparency. The company’s 200+ employees across 4 offices worldwide serve more than 225 enterprise customers. More information can be found at www.riskmethods.net.
About Blackstone
Blackstone is the world’s largest alternative investment firm. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $941 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005415/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
